Q-omics provides the consensus-scored INO80D profile across patient tissues and cancer cell-line models. INO80D expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, INO80D is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, INO80D RNA expression shows 22,291 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KICH as cancer lineages where INO80D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for INO80D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes INO80D survival associations across molecular data types. INO80D RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible INO80D RNA expression–survival associations across cancer types. High INO80D expression shows unfavorable associations in ACC, LIHC, UVM and CESC, but favorable associations in KIRC and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for INO80D RNA expression.
This table summarizes INO80D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in LIHC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for INO80D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. INO80D shows lower tumor expression in KICH and UCEC and higher tumor expression in LIHC, STAD, KIRC and CHOL. The KICH box plot shows higher INO80D RNA expression in normal versus tumor tissue (log2 FC = −0.701, t-test p < 0.001).
This table shows molecular features associated with INO80D in patient tissues and cancer cell lines. In patient samples, INO80D shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, INO80D RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LARGE_INTESTINE.
